Cushing's syndrome induced by betamethasone nose drops

BMJ 1999; 318 doi: https://doi.org/10.1136/bmj.318.7194.1355 (Published 15 May 1999) Cite this as: BMJ 1999;318:1355

In rhinological disease betamethasone should be regarded as systemic corticosteroid

  1. Jarrod J Homer, Specialist registrar in otorhinolaryngology,
  2. Tasso G Gazis, Specialist registrar in endocrinology
  1. St James's University Hospital, Leeds LS9 7TF
  2. Queen's Medical Centre, University Hospital, Nottingham NG7 2UH
  3. Center for Drug Evaluation and Research, US Food and Drug Administration, Rockville, MD 20857 USA
  4. Department of Paediatrics, Royal Gwent Hospital, Newport NP9 2UB craig.hiatt@swansea-tr.wales.nhs.uk

    EDITOR—We agree with Findlay et al that the few case reports of Cushing's syndrome due to nasal betamethasone drops in children may represent the tip of the iceberg.1 With colleagues we have performed a prospective study in nine adults with nasal polyposis treated with betamethasone drops for six weeks; we assessed the hypothalamopituitary-adrenal axis using a low dose (1 μg) tetracosactrin stimulation test, which may detect more subtle impairment of endogenous cortisol production than the standard test (250 μg).2 We found that all patients had significantly depressed cortisol concentrations when tetracosactrin was given after betamethasone treatment (figure; P<0.0001, analysis of variance for repeated measures).3

    Result of low dose tetracosactrin stimulation test before and after six weeks' treatment with betamethasone nose drops

    Gallagher and Mackay have suggested that in many cases patients tend to overcomply with treatment with nasal drops owing largely to difficulties in using the droplet dispenser.4 The perceived benefit of betamethasone over other topical nasal steroids is that its intranasal distribution is superior (because it is in drop form) to that …

    View Full Text

    Sign in

    Log in through your institution